Supplementary Figure S3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Genes differentially expressed as a function of BOR on cycle 3 day 1. Genes differentially expressed on C3D1 versus treatment baseline, as a function of TPST-1120 exposure. Linear associations of C3D1 Log2 fold change in expression levels of indicated genes and TPST-1120 AUC0-24. Data are shown for both TPST-1120 monotherapy (part 1) and TPST-1120 + nivolumab combination therapy (part 2).